Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. million DNA bases. Muscles stop working.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

OCTOBER 4, 2023

The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. 2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Codon

AUGUST 27, 2024

Allison Berke makes the case for real-time DNA sequencing and AI tools to detect pathogens before they spread widely. Reading DNA The first step in detecting a novel pathogen is recognizing it as an anomaly amidst a noisy background of other material. After copying the DNA to form a big pool, each piece is sequenced.

DNA 99

DNA Laboratories Hospitals Virus 99

Broad Institute

JULY 11, 2024

Reporting in Science , researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard have made a surprising discovery about these drugs. They found that mIDH1 inhibitors trick the tumor cells into thinking they are infected with a virus, causing the immune system to mount an antiviral response.

Treatment 72

Treatment Immune Response Drugs Virus 72

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

APRIL 26, 2023

Gene-editing methods allow researchers to modify DNA, resulting in alterations in physical characteristics such as eye colour and susceptibility to diseases. To achieve this, scientists utilise various technologies that function similarly to scissors, precisely cutting the DNA at a particular location.

RNA 98

RNA Medical Schools Engineering Disease 98

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

PLOS: DNA Science

SEPTEMBER 5, 2024

Researchers from Harvard Medical School describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer.

Treatment 71

Treatment FDA Approval DNA Small Molecule 71

Drug Target Review

JANUARY 15, 2024

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. To be therapeutically useful, antigenic peptides must be presented in a way that allows immune responses to destroy cancer cells without causing unacceptable damage to healthy tissue.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

MAY 14, 2024

Since cancer cells are under chronic stimulation of ER stress, the polypeptides cannot activate innate immune sensors in cancer cells even upon the polypeptide treatment. Which natural agonists impede the activation of intracellular DNA sensors in APCs, and what challenges do they pose?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

DrugBank

MAY 15, 2024

Researchers would sift through natural extracts , hoping to stumble upon a compound that exhibited beneficial effects. In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

PLOS: DNA Science

OCTOBER 3, 2024

A research team led by Rita Fior at the Champalimaud Centre for the Unknown, Lisbon, Portugal, figured out how BCG decimates cancer cells. However, the modern science of immunology has shown that Coley’s principles were correct and that some cancers are sensitive to an enhanced immune system. The approach worked.

Vaccine 52

Vaccine Immune Response DNA Treatment 52

Codon

FEBRUARY 13, 2024

Goodsell, RCSB Protein Data Bank and Scripps Research. 1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. Still, researchers are trying. Read it on our website here. Illustration by David S.

Therapies 128

Therapies Virus DNA Clinical Trials 128

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms. Because of that, the researchers wondered if STING might somehow induce proton leakage.

Regulations 91

Regulations Clinical Trials Engineering Science 91

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. These options are creating opportunities to develop more sophisticated, novel combination regimens for patients.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Codon

SEPTEMBER 29, 2024

mRNA was the intermediate stage between DNA and protein, a dynamic entity that shifted depending on the second-to-second needs of the cell, able to point out if a cell was cancerous or stressed, what kind of cell it was, and so on. The lab created a plan with eight research institutions across three continents.

Engineering 140

Engineering Virus DNA Therapies 140

PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Engineering 52

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

Broad Institute

AUGUST 11, 2022

A team led by researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT has discovered and characterized one of these unexplored microbial defense systems. In the new study, the researchers wanted to know if the proteins work the same way in prokaryotes to defend against infection.

DNA 52

DNA Virus Immune Response Bioinformatics 52

Codon

DECEMBER 12, 2024

Among the report’s authors are 16 members of national academies, two Nobel Laureates, and several researchers who have previously been frontrunners in the quest to create mirrored life. ” 1 Now, it seems, these researchers have changed their minds. 4 As far as we know, right-handed proteins never occur naturally.

DNA 104

DNA RNA Vaccine Virus 104

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Immune Response Therapies Treatment 52

Conversations in Drug Development Trends

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Microenvironment Management : Optimizing the tumor microenvironment to enhance TIL efficacy remains a critical focus of research efforts.

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. in North America) in late 2017.

Science 105

Science Clinical Development Treatment DNA 105

DrugBank

MARCH 12, 2025

Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. This process triggers a robust immune response, enabling the immune system to recognize and attack cancer cells. Another challenge is the potential for unintended immune responses.

Vaccine 52

Vaccine Treatment Clinical Trials Therapies 52

PLOS: DNA Science

JANUARY 4, 2024

.” CRISPRs are short DNA sequences, peppered with repeats, that latch onto DNA-cutting enzymes, commandeering and directing them to snip certain parts of a chromosome. The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response.

FDA Approval 52

FDA Approval DNA Therapies Clinical Trials 52

Drug Target Review

OCTOBER 2, 2024

Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies.

Therapies 98

Therapies Disease Engineering RNA 98

Drug Target Review

DECEMBER 13, 2024

Innovations in payload substances, such as topoisomerase inhibitors (topo-1i), and next-generation DNA- damaging agents to replace older, more toxic agents. However, research and clinical trials of BiTEs in solid tumours, including NSCLC, are still in the early phases. Biomarker Research. 2024;12(1):24. Curr Probl Cancer.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Drug Target Review

DECEMBER 5, 2024

Among them, adeno-associated viruses (AAVs) stand out due to their small size, high efficiency in gene delivery, low immunogenicity, and potential for customisable tissue targeting, making them the leading tool in gene expression research.

Therapies 52

Therapies Virus DNA Compliance 52

LifeSciVC

JULY 1, 2024

So when I was asked recently to share advice to a group of undergraduate students doing research at Penn State, I was drawn to the idea of connecting scientific principles to some life lessons. The central dogma of molecular biology is that information generally (with few exceptions) flows from DNA to RNA to Protein.

Science 86

Science Immune Response Molecular Biology RNA 86

The Pharma Data

JANUARY 18, 2021

Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. This agreement does not impact Neurophth Therapeutics’ ongoing research in glaucoma, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Therapies 52

Therapies Immune Response DNA Treatment 52

The Pharma Data

MAY 15, 2023

“The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases,” said Flavius Martin, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Codon

JULY 27, 2023

I could write an entire article in response, but if you want to go deeper into this subject, I suggest you read it in full. For a recent study, researchers edited 21 different genes in poplar trees, a species commonly used to make paper. The researchers studied trees with 70,000 different gene-editing combinations, just 0.5%

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

I could write an entire article in response, but if you want to go deeper into this subject, I suggest you read it in full. For a recent study, researchers edited 21 different genes in poplar trees, a species commonly used to make paper. The researchers studied trees with 70,000 different gene-editing combinations, just 0.5%

Therapies 52

Therapies RNA DNA Engineering 52